A Role for Glutathione in the Pathophysiology of Bipolar Disorder and Schizophrenia? Animal Models and Relevance to Clinical Practice
Open accessThe DOI matches its Crossref record.
Abstract
The tripeptide, glutathione (gamma-glutamylcysteinylglycine) is the primary endogenous free radical scavenger in the human body. When glutathione (GSH) levels are reduced there is an increased potential for cellular oxidative stress, characterised by an increase and accruement of reactive oxygen species (ROS). Oxidative stress has been implicated in the pathology of schizophrenia and bipolar disorder. This could partly be caused by alterations in dopaminergic and glutamatergic activity that are implicated in these illnesses. Glutamate and dopamine are highly redox reactive molecules and produce ROS during normal neurotransmission. Alterations to these neurotransmitter pathways may therefore increase the oxidative burden in the brain. Furthermore, mitochondrial dysfunction, as a source of oxidative stress, has been documented in both schizophrenia and bipolar disorder. The combination of altered neurotransmission and this mitochondrial dysfunction leading to oxidative damage may ultimately contribute to illness symptoms. Animal models have been established to investigate the involvement of glutathione depletion in aspects of schizophrenia and bipolar disorder to further characterise the role of oxidative stress in psychopathology. Stemming from preclinical evidence, clinical studies have recently shown antioxidant precursor treatment to be effective in schizophrenia and bipolar disorder, providing a novel clinical angle to augment often suboptimal conventional treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Self-citationMoylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Self-citationN-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action
Dean, O., Giorlando, F., & Berk, M. (2011) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.100057 · Cited by 494
Self-citationNutritional psychiatry: The present state of the evidence
Marx, W., Moseley, G., Berk, M., & Jacka, F. (2017) · Proceedings of the Nutrition Society · doi:10.1017/s0029665117002026 · Cited by 469
Self-citationOxidative stress in schizophrenia: An integrated approach
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.008 · Cited by 472
The promise of N-acetylcysteine in neuropsychiatry
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.01.001 · Cited by 434
Self-citationAspirin: a review of its neurobiological properties and therapeutic potential for mental illness
Berk, M., Dean, O., Drexhage, H., McNeil, J. J., Moylan, S., O'Neil, A., Davey, C. G., Sanna, L., & Maes, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-74 · Cited by 391
Self-citationMelnyk, S., Fuchs, G. J., Schulz, E., Lopez, M., Kahler, S. G., Fussell, J. J., Bellando, J., Pavliv, O., Rose, S., Seidel, L., et al. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1260-7 · Cited by 250
“Similar evidence of oxidative stress in blood, CSF and brain has been similarly reported in patients with schizophrenia and bipolar disorder (Andreazza et al. 2009; Dean et al. 2009).”
Calcium signalling and psychiatric disease: bipolar disorder and schizophrenia
Berridge, M. J. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1806-z · Cited by 181
“The deleterious effects of ROS may be increased by a decline in the levels of the antioxidant glutathione (GSH; Dean et al. 2009).”
BackgroundBerk, M., Dean, O., Cotton, S. M., Gama, C. S., Kapczinski, F., Fernandes, B. S., Kohlmann, K., Jeavons, S., Hewitt, K., Allwang, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.005 · Cited by 181
Self-citationAnimal models of bipolar mania: The past, present and future
Logan, R. W., & McClung, C. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.041 · Cited by 136
Hassan, W., Barroso Silva, C., Mohammadzai, I. U., Teixeira da Rocha, J., & Landeira-Fernandez, J. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120232135 · Cited by 100
“Other studies have reported the involvement of oxidative stress in bipolar disorder, schizophrenia, hypertension, and depression [19, 36-37].”
Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder
Pfaffenseller, B., Fries, G. R., Wollenhaupt-Aguiar, B., Colpo, G. D., Stertz, L., Panizzutti, B., Magalhães, P. V., & Kapczinski, F. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811981 · Cited by 68
A preliminary investigation on the efficacy of N -acetyl cysteine for mania or hypomania
Vieira da Silva Magalhães, P., Dean, O. M., Bush, A. I., Copolov, D. L., Malhi, G. S., Kohlmann, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Berk, M. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413481631 · Cited by 58
“With these new findings, there is growing interest in developing new interventions that directly target oxidative biology in bipolar disorder (Dean et al., 2009; Ng et al., 2008).”
BackgroundSelf-citationOrhan, N., Kucukali, C. I., Cakir, U., Seker, N., & Aydin, M. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.09.012 · Cited by 36
Metadata
- Authors
- Dean, O., den Buuse, M., Bush, A. I., Copolov, D. L., Ng, F., Dodd, S., & Berk, M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-08-01
- Volume
- 16
- Issue
- 23
- Pages
- 2965-2976
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2096856875
- Cited by
- 101
- References
- 0
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.